Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.61 |
| ▸ | CTSB | P07858 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 1/20 | 0.61 |
| ▸ | TACR1 | P25103 | 2/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7600777 | 1.00 | CTSL (0.61) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL2411802 | 0.89 | TACR1 (0.66) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL7275662 | 0.89 | CTSL (0.58) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL7275672 | 0.89 | CTSL (0.58) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL1264475 | 0.88 | CTSL (0.59) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL31397615 | 0.87 | CAPN1 (0.72) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL9088735 | 0.87 | CAPN1 (0.72) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL10967811 | 0.87 | CAPN1 (0.72) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL7281206 | 0.87 | CAPN1 (0.72) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL5484209 | 0.87 | CAPN1 (0.72) | CTSLCTSBCTSSCTSKTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879574-B2 | Folded peptide backbone each end of which is conjugated to a fluorophore, which when cleaved as by digestion with a protease, the fluorophores provide high intensity signals; histology | ONCOIMMUNIN, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080199898-A1 | COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF | ONCOIMMUNIN, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7312302-B2 | Compositions for the detection of enzyme activity in biological samples and methods of use thereof | ONCOLMMUNIN, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20040096926-A1 | Compositions for the detection of enzyme activity in biological samples and methods of use thereof | ONCOIMMUNIN, INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040096926-A1 | Compositions for the detection of enzyme activity in biological samples and methods of use thereof | PRSS3, PREP, CTRL | CTSL 74/4885CTSB 56/4885CTSS 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.